Phase 3 Readout~month

Phase 3 Topline: COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCAN

Drug
common
Indication
Human Papilloma Virus (HPV); Warts; Common Warts

Other upcoming events for VRCA

Phase 3 ReadoutPhase 3 Topline: COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S
Phase 3 ReadoutPhase 3 Topline: COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S
Patent ExpiryPatent/Exclusivity Expiry: YCANTH

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCAN — VRCA Phase 3 Readout | BioSniper